National Cancer Institute, Research Contracts Branch, PSAS, 6120 Executive Blvd, EPS/Room 638, Bethesda, MD 20892-7227

A -- SERVICES TO COMPLETE A COLLABORATION STUDY FO CANCER RISK AND RADIATION DOSE SOL RFQ90078(NS) DUE 041699 POC Patricia Haun, Purchasing Agent & Todd Cole, Contracting Officer The Radiation Epidemiology Branch (REB), Division of Cancer Epidemiology & Genetics (DCEG), National Cancer Institute (NCI), plans to procure from Reinart Beheer B.V., Malpertuisplein 60, 6217 CD Maastricht, Netherlands, services to complete a collaboration study of cancer risk and radiation dose. Nasopharyngeal irradiation treatment was introduced in 1926 and became obsolete by the 1960s. In 1989, Dr. Verduijn, of the Reinaert Kliniek, published a study of cancer mortality among subjects who had been treated for eustachian tube blockage. More recently, the study was reactivated and substantially increased in size and scope, to include a new follow-up of cancer risk and exposure information in a cohort of 10,000 persons treated as children at various ear, nose and throat (ENT) clinics in the Netherlands. The study was initially supported through a support services contract (N01-CP-33013) which is now expired. The study identified patients that were treated at various ENT clinics and a health surveyquestionnaire was mailed to all living participants to inquire about personal history of cancer and to collect data on risk factors. The purpose of this requirement is to complete new study by finalizing all data collection, performing statistical analyses to relate cancer risk to site-specific radiation dose, and preparing a manuscript for publication. In this completion effort, all remaining patients with whom contact has not been made (or all avenues of contact have not yet been exhausted) will be followed up by letter and telephone. Reported causes of death will be verified through linkage with the Central Bureau of Statistics in the Netherlands. Reports of cancer shall be validated with the subject's physician or through the Netherlands Cancer Registry. Follow-up to maximize responses shall also be performed. Data sets shall result from the follow-up and shall be provided to NCI. This data shall be comparable to that received previously from Dr. Verduijn. Observed cancer frequencies for patients treatedwith radium and by other means, can then be compared with expected numbers calculated according to population rates. Relative risks will be estimated for mortality and incidence as functions of cancer site, age at treatment and at observation for risk, sex and radiation dose. The cohort utilized by Dr. Verduijn is a unique resource, as the subjects have already been identified, and followed up from over ten years ago. The proposed requirement is to complete the work begun and performed under contract, N01-CP-33013. In addition, Dr. Verduijn is a published expert in the field of radium implants, and he is an ENT physician. Since the continuity and reliability of results must be maintained, the Reinart Beheer, B.V. clinic through Dr. Verduijn is the only source known to NCI that can complete this study and maintain the reliability of all data. This is not a request for competitive quotations. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities.The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can meet the above specifications. Capability statements must be received in the contracting office by 1:00 p.m. EST, on April 16, 1999. If you have any questions, please contact Patricia Haun, Purchasing Agent on (301) 402-4509. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Posted 03/31/99 (W-SN314743). (0090)

Loren Data Corp. http://www.ld.com (SYN# 0006 19990402\A-0006.SOL)